Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Avid Radiopharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects diagnosed by a dementia specialist with symptomatic clinical syndromes with expected Frontotemporal Dementia (FTD) pathology will be enrolled. Clinical syndromes associated with FTD pathology include: behavioral-variant FTD, FTD with motor-neuron disease, non-fluent/agrammatic and semantic variants of primary progressive aphasia, progressive supranuclear palsy syndrome and corticobasal syndrome.
Have provided informed consent or have a legally authorized (LAR) provide consent for study procedures
Have had volumetric brain MRI obtained in site's companion protocol within one year of enrollment
Can tolerate PET scan procedures
You may not be if
Have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances that pose potential safety risk
Have history of risk factors for Torsades de Pointes (TdP) or taking medication known to cause QT prolongation
Have history of drug or alcohol dependence within the last year
Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraception
Have history of relevant severe drug allergy or hypersensitivity
Have received an investigational medication under FDA IND protocol within 30 days of planned imaging session
Have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging session
Possess PET scan evidence of amyloid deposition
Determined by the investigator to be unsuitable for this type of study
Clareo Health | Flortaucipir PET Imaging in Subjects With FTD
